BMJ 2001;322:329-333 ( 10 February )

Papers

Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review

Lelia Duley, obstetric epidemiologist, ^a David Henderson-Smart, director, ^c Marian Knight, specialist registrar, ^b James King, director. ^d

^a Resource Centre for Randomised Trials, Institute of Health Sciences, Oxford OX3 7LF, ^b Health Services Research Unit, Institute of Health Sciences, ^c New South Wales Centre for Perinatal Health Services Research, Queen Elizabeth II Institute for Mothers and Infants, Sydney, Australia, ^d Perinatal Epidemiology Unit, Mater Hospital, Brisbane, Australia

Correspondence to: L Duley lelia.duley{at}ndm.ox.ac.uk

Objective: To assess the effectiveness and safety of antiplatelet drugs for prevention of pre-eclampsia and its consequences.
Design: Systematic review.
Data sources: Register of trials maintained by Cochrane Pregnancy and Childbirth Group, Cochrane Controlled Trials Register, and Embase.
Included studies: Randomised trials involving women at risk of pre-eclampsia, and its complications, allocated to antiplatelet drug(s) versus placebo or no antiplatelet drug.
Main outcomes measures: Pre-eclampsia, preterm birth, fetal or neonatal death, and small for gestational age baby. Studies were assessed for quality of concealment of allocation and losses to follow up.
Results: 39 trials (30 563 women) were included, and 45 trials (>3000 women) excluded. Use of antiplatelet drugs was associated with a 15% reduction in the risk of pre-eclampsia (32 trials, 29 331 women; relative risk 0.85, 95% confidence interval 0.78 to 0.92; number needed to treat 100, 59 to 167). There was also an 8% reduction in the risk of preterm birth (23 trials, 28 268 women; 0.92, 0.88 to 0.97; 72, 44 to 200), and a 14% reduction in the risk of fetal or neonatal death (30 trials, 30 093 women; 0.86, 0.75 to 0.98; 250, 125 to >10 000) for women allocated antiplatelet drugs. Small for gestational age babies were reported in 25 trials (20 349 women), with no overall difference between the groups (relative risk 0.92, 0.84 to 1.01). There were no significant differences in other measures of outcome.
Conclusions: Antiplatelet drugs, largely low dose aspirin, have small to moderate benefits when used for prevention of pre-eclampsia.

---

© BMJ 2001
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Relevant Article

Antiplatelet drugs lower the risk of pre-eclampsia
BMJ 2001 322: 0. [Full Text]

This article has been cited by other articles:

• Patrono, C., Baigent, C., Hirsh, J., Roth, G. (2008). Antiplatelet Drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 199S-233S [Abstract] [Full text]  
• Schroder, H. (2005). New signaling routes for an old drug: lipoxin A4 might mediate heme oxygenase-1 induction by aspirin. Focus on "Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells". Am. J. Physiol. Cell Physiol. 289: C507-C508 [Full text]  
• Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J., Roth, G. (2004). Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 234S-264S [Abstract] [Full text]  
• Shennan, A. H (2003). Recent developments in obstetrics. BMJ 327: 604-608 [Full text]  
• Roberts, J. M., Pearson, G., Cutler, J., Lindheimer, M. (2003). Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertension 41: 437-445 [Abstract] [Full text]  
• Leonhardt, A., Bernert, S., Watzer, B., Schmitz-Ziegler, G., Seyberth, H. W. (2003). Low-Dose Aspirin in Pregnancy: Maternal and Neonatal Aspirin Concentrations and Neonatal Prostanoid Formation. Pediatrics 111: e77-81 [Abstract] [Full text]  
• Khalil, R. A., Granger, J. P. (2002). Vascular mechanisms of increased arterial pressure in preeclampsia: lessons from animal models. Am. J. Physiol. Regul. Integr. Comp. Physiol. 283: R29-R45 [Abstract] [Full text]  
• Rahman, T.M., Wendon, J. (2002). Severe hepatic dysfunction in pregnancy. QJM 95: 343-357 [Abstract] [Full text]  
• Hannah, M. E (2001). Review: antiplatelet drugs reduce pre-eclampsia, preterm birth, and stillbirth or neonatal death. Evid. Based Med. 6: 107-107 [Full text]  
• (2001). Aspirin of Small Benefit in Preventing Preeclampsia. JWatch General 2001: 4-4 [Full text]  

Rapid Responses:

Read all Rapid Responses

Clinically useful presentation of results

Deirdre J Murphy
bmj.com, 19 Feb 2001 [Full text]

Aspirin has clinically significant benefit in high risk groups - Summary NNT can mislead clinicians

A Coomarasamy
bmj.com, 21 Feb 2001 [Full text]

Online poll

Find out more >>